Is the beauty sector still attractive?
While beauty, cosmetics and skincare firms bet big on China, a tougher market threatens their premium valuations
![Frame with gift, sequins, beauty and makeup cosmetics kit](https://cdn.mos.cms.futurecdn.net/YBZdNmAzsZohBcuhULWEXa-415-80.jpg)
Beauty has been a popular sector among investors who like high-quality companies. These brands were seen as relatively defensive: even in a recession, customers were likely to keep buying their favourite products as an affordable luxury. And there was good potential for growth since customers in emerging markets would buy more cosmetics and high-end skincare from desirable foreign brands as they became wealthier. So a slump last week in the shares of Japan’s Shiseido and South Korea’s Amorepacific is worth noting.
Shiseido is off almost 24% after disappointing results that showed continued weak demand in China. As a one-off, this might not be a complete shock: the company had also reported weak full-year results for 2023 driven by China and had already announced plans to cut costs and improve profitability. Its shares peaked in 2019 and have been looking weak since mid-2023. However, Amorepacific fell a similar amount after earnings missed expectations, with continued weak demand in China. Looking back further, US group Estée Lauder had a dire 2023 on the back of problems… yes, China. So all this is starting to look like a bit of a worrying pattern.
Is investing in the beauty sector worth it?
It seems clear that the market that once offered the greatest promise for global beauty – and provided much of the justification for why these firms should trade on elevated valuations – is becoming very challenging. There are two likely factors. First, underlying growth and consumer demand in China continue to be weak. Second, consumers may be turning more towards local brands for reasons that range from value for money to nationalism or domestic pride.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
![https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg](https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748-320-80.jpg)
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Shiseido says that controversy over the release of treated water from the Fukushima nuclear power plant is affecting demand for Japanese products (misinformation about this is widespread in China). Such risks are not new. When South Korea agreed in 2016 to allow a US missile defence system to be deployed in the country, there were government-backed campaigns to boycott South Korean products. Amorepacific’s share price has never regained the bubbly peak it hit back then and, like, Shiseido has been on a wobbly downtrend for a while.
Earnings forecasts for the beauty sector imply a decent rebound even for the underperformers in 2025. Yet in China, competition from local brands is likely to get tougher. Rules that will force cosmetics firms to disclose the precise composition of their products to regulators have raised concerns about whether this could mean trade secrets get leaked. And the China risks put a lot of weight on the US and Europe to be steady and other emerging markets to show growth. Most firms now trade on price/earnings ratios in the 20-25 range based on estimates for 2025. There are some excellent stocks in this sector: I still hold L’Oréal in my multinationals portfolio, alongside diversified groups such as Procter & Gamble and Unilever. But as with other consumer stories that have recently disappointed, there is a risk that valuations come down across the board.
This article was first published in MoneyWeek's magazine. Enjoy exclusive early access to news, opinion and analysis from our team of financial experts with a MoneyWeek subscription.
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
Cris Sholto Heaton is an investment analyst and writer who has been contributing to MoneyWeek since 2006 and was managing editor of the magazine between 2016 and 2018. He is especially interested in international investing, believing many investors still focus too much on their home markets and that it pays to take advantage of all the opportunities the world offers. He often writes about Asian equities, international income and global asset allocation.
Cris began his career in financial services consultancy at PwC and Lane Clark & Peacock, before an abrupt change of direction into oil, gas and energy at Petroleum Economist and Platts and subsequently into investment research and writing. In addition to his articles for MoneyWeek, he also works with a number of asset managers, consultancies and financial information providers.
He holds the Chartered Financial Analyst designation and the Investment Management Certificate, as well as degrees in finance and mathematics. He has also studied acting, film-making and photography, and strongly suspects that an awareness of what makes a compelling story is just as important for understanding markets as any amount of qualifications.
-
Apple loses court battle over €13bn tax bill - should you invest?
The case against Apple was brought by the European Commission and ends an eight-year dispute
By Chris Newlands Published
-
“Fast-track justice” goes off the rails: is it time to rethink the system?
Single Justice Procedures, or fast-track justice, designed to deal with minor offences, have become increasingly heavy-handed. Is it time for an overhaul?
By Simon Wilson Published
-
The peak of the AI frenzy has passed
When did the AI frenzy peak and what does it mean for tech companies?
By Alex Rankine Published
-
The battle against heart disease and how to invest in it
Heart disease is soaring due to rising obesity and an ageing population. But new drugs, treatments and diagnostic tools are on the way.
By Dr Matthew Partridge Published
-
Woodside Energy: an undervalued energy play
Woodside Energy offers a cheap way to invest in the growth of the global LNG market. Should you invest?
By Rupert Hargreaves Published
-
Small caps: how to ride the recovery wave of UK equities
Professional investor Ken Wotton highlights British small caps that hit the sweet spot of the British equity market
By Ken Wotton Published
-
Investing in defence: the easiest way to buy into the boom
The defence sector has taken off, but the opportunities for stock picking are more limited. We explain what to buy
By Frederic Guirinec Published
-
Should the FCA allow crypto ETP for retail trade?
ETPs could make cryptocurrency safer for everyone, so it’s odd that the regulator won’t let retail traders use them
By Ben Judge Published
-
The investment opportunities in a bear market
As equities fell sharply in August, Max King explores the investment opportunities in a bear market
By Max King Published
-
How to invest in Web 3.0
Here are three core holdings at the forefront of Web 3.0 development that could shape the next era of the internet, according to Chanchal Samadder, head of product at ETC Group
By Chanchal Samadder Published